Summary Lipid metabolism has been considered recently as a novel target for cancer therapy. In this field, lithium gamma-linolenate (LiGLA) is a promising experimental compound for use in the treatment of human tumours. In. vivo and in vitro studies allowed us to assess the metabolism of radiolabelled LiGLA by tumour tissue and different organs of the host. In vitro studies demonstrated that human pancreatic (AsPC-1), prostatic (PC-3) and mammary carcinoma (ZR-75-1) cells were capable of elongating GLA from LiGLA to dihomo-gamma-linolenic acid (DGLA) and further desaturating it to arachidonic acid (AA). AsPC-1 cells showed the lowest A5-desaturase activity on DGLA. In the in vivo studies, nude mice bearing the human carcinomas were given Li[1-14C]GLA (2.5 mg kg-') by intravenous injection for 30 min. Mice were either sacrificed after infusion or left for up to 96 h recovery before sacrifice. In general, the organs showed a maximum uptake of radioactivity 30 min after the infusion started (t = 0). Thereafter, in major organs the percentage of injected radioactivity per g of tissue declined below 1% 96 h after infusion. In kidney, brain, testes/ovaries and all three tumour tissues, labelling remained constant throughout the experiment. The ratio of radioactivity in liver to tumour tissues ranged between 16-and 24-fold at t = 0 and between 3.1-and 3.7-fold at 96 h. All tissues showed a progressive increase in the proportion of radioactivity associated with AA with a concomitant decrease in radiolabelled GLA as the time after infusion increased. DGLA declined rapidly in liver and plasma, but at a much slower rate in brain and malignant tissue. Seventy-two hours after the infusion, GLA was only detected in plasma and tumour tissue. The sum of GLA + DGLA varied among tumour tissues, but it remained 2-4 times higher than in liver and plasma. In brain, DGLA is the major contributor to the sum of these fatty acids. Data showed that cytotoxic GLA and DGLA, the latter provided either by the host or by endogenous synthesis, remained in human tumours for at least 4 days.
INTRODUCTION
Gamma-linolenic acid (GLA; 18:3n-6) and dihomo-gammalinolenic acid (DGLA 20:3n 6)' both with three double bonds in the cis configuration, have been shown to have a wide range of anticancer and/or antiproliferative effects (Horrobin, 1994; Jiang et al, 1995) . These n-6 fatty acids are derived from linolenic acid (18:2fn6) and can be converted to arachidonic acid (AA; 20:4fn 6)' as shown in Figure 1 .
Co-culture experiments in which normal and malignant cells were cultured together in the same dish demonstrated that cancer cells were selectively responsive to GLA and its elongation product, DGLA, when added to the culture medium at concentrations that do not harm normal cells (Begin et al, 1986) . In contrast, arachidonic acid, the A5 desaturation product of DGLA, exhibits cytotoxic effects on cancer cells but is not as selective as its precursors (Begin, 1987) .
One possible mechanism of action is based on the fact that these n-6 fatty acids can bypass the A6-desaturase deficiency reported in some malignant cells and/or restore towards normal the low levels of polyunsaturated fatty acids detected in certain cancer patients (van Hoeven and Emmelot 1973; Feraon et al, 1996) . On exposure to GLA the cancer cells generate higher levels of superoxide radicals, lipid peroxidation products and/or eiscosanoids, many of which compounds have anti-tumour properties (Sakai and Yamaguchi, 1984; Das et al, 1987; Takeda et al, 1992) .
Furthermore, GLA seems to have the ability to induce apoptosis (de Kock et al, 1994) and to inhibit a range of mechanisms responsible for metastasis. Indeed, GLA has now been shown to restore defective E-cadherin function in human lung, colon, breast, melanoma and liver cancer cells, with a corresponding loss of invasiveness (Jiang et al, 1995) . GLA or its metabolites were 18:3 (GLA) ongation ( AA, arachidonic acid (20:4,,6); 22:3,r6, direct elongation product of DGLA; ADA, adrenic acid (22:4,,6) effective in inhibiting enzymes associated with metastasis or closely correlated with metastatic potential such as urokinase (du Toit et al, 1994) , 12-lipoxygenase (Honn et al, 1994; Ziboh, 1996) and 5-lipoxygenase (Ziboh, 1996) . In addition, GLA inhibits cell-matrix interactions and so GLA exerts inhibitory effects at several stages in the multistep process of tumour formation and progression (Jiang et al, 1996) .
Particularly promising therapeutic effects were obtained with the administration of GLA directly into the tumour cavity in patients with malignant glioblastomas and astrocytomas (Das et al, 1995) . The tumours regressed and survival was substantially prolonged. The inhibitory effect of GLA on the growth of a human lung mucoepidermoid carcinoma, breast cancer and malignant melanoma (de Bravo et al, 1994; Pritchard et al, 1989) was also observed in immunodeficient animal models.
In most of these studies GLA was either administered orally in the form of triglyceride, ester or free fatty acid or injected intravenously in the form of the relatively water-soluble lithium salt (Fearon et al, 1996) . Potassium salts were not considered because of potentially adverse cardiac effects. The lithium salt had an advantage over the sodium salt in that the rate of infusion could be monitored by measuring the lithium blood concentrations with routine hospital analytical techniques. Toxicity of lithium is not a concern if the serum levels of lithium remain below those commonly used in chronic psychiatric treatments (Fearon et al, 1996) . A phase II1 dose escalation study in patients with inoperable pancreatic cancer showed that the higher doses of LiGLA were associated with longer survival times without an important adverse outcome and, in particular, without the serious effects commonly related with chemotherapy (Fearon et al, 1996) .
As unsaturated lipids are now serious candidates for novel anticancer drugs, it is important to understand the metabolism of LiGLA in cancer patients. We have therefore examined the in vivo and in vitro uptake, elongation and further desaturation of radiolabelled LiGLA by three human carcinomas. connected to a computerized system. Tumour volume was calculated for an ellipsoid by the formula V = 1 x w x h/2, where 1 is the length, w is the width and h is the height, in millimetres.
MATERIALS AND METHODS

Li[1 -14C]GLA administration
In the in vivo experiments conditions were designed to mimic, as much as is possible in an animal model, the infusion protocol followed with cancer patients (Fearon et al, 1996) .
At approximately 300 mm3 tumour volume animals were anaesthetized with sodium pentobarbital (80 mg kg-'; Somnotol, MTC Pharmaceuticals, Cambridge, Ontario, Canada). Mice were then given 125 jil of 0.9% sodium chloride with 200 IU kg-' heparin and 14 ,uCi of Li[1-'4C]GLA (more than 98% radiochemical purity; 58 gCi jimol-1; New England Nuclear) by slow intravenous injection through the tail vein (2.53 mg kg-' over 30 min) using a paediatric 27 G butterfly and infusion pump.
Mice were sacrificed either immediately after the 30 min infusion (time 0) or left for recovery for either 24, 48 or 96 h until sacrifice by exsanguination under halothane anaesthesia.
Organs were perfused (via the heart left ventricle, vena cava and portal vein) and rinsed with cold 0.9% sodium chloride and blotted dry. Aliquots of each tissue were solubilized with Solvable 0.5 M (New England Nuclear) at 56°C.
In order to reduce chemiluminescence, samples were decolorized with hydrogen peroxide and neutralized with glacial acetic acid before adding the cocktail (Formula 989, New England Nuclear) for scintillation counting.
Lipid analysis
Lipids from malignant cell suspensions and from organ and tumour tissues were extracted with chloroform-methanol (2:1, v/v) (Folch et al, 1957) . The total lipid extract was methylated using boron fluoride in methanol at 90°C for 30 min (Morrison and Smith, 1964) . The resultant radiolabelled fatty acid methyl esters (FAMEs) were analysed as previously described (de Antueno et al, 1994 GLA metabolites Liver, brain and tumour tissue were examined for the presence of radiolabelled elongation and A5 desaturation products of GLA (Figure 4 ). Data from plasma were also included. Liver and brain were selected as they provided enough material for the HPLC analysis and because they are potential sites for the development of metastatic malignant tumours.
An unidentified radiolabelled compound that may be 22:3fn6, the direct elongation product of DGLA, was not included in the figures. The levels of this fatty acid did not exceed 3-4% of total radioactivity recovered at early time points in host livers and plasma whereas, in tumour tissue, those concentrations were only detected within 24-96 h after infusion. All tissues showed a progressive increase in the proportion of radioactivity associated with AA with a concomitant decrease in radiolabelled GLA as the time after infusion increased. DGLA levels declined rapidly in liver and plasma but at a much slower British Journal of Cancer (1997) When all these data were calculated in terms of microgram per gram of tissue, the findings were also consistent with those based on the percentage data. For example, for AsPC-1 host mice at 48 h, the liver contents of DGLA and AA were 0.35 and 2.99 ,ug g-' respectively, whereas in the pancreatic carcinoma the levels of GLA, DGLA and AA were 0.06, 0.16 and 0.20 ,ug g-' respectively. This represents a concentration of about 0.42 jig of total n-6 PUFAs produced from Li[l-l4C]GLA per ml of tumour tissue, assuming unit density of malignant tissue (Houchens and Ovejera, 1991) . Table 1 shows that tumour (in particular AsPC-1 and PC-3) and brain tissues maintained higher ratios of GLA+DGLA/AA than plasma and liver tissue for 48-96 h after infusion. Differences were observed among tumours but, by 96 h after infusion, the ratio slowly decreased 4 and 12 times in AsPC-1 and PC-3 respectively, whereas in liver the ratio declined 15-fold. ZR-75-1 tumours showed exceptionally lower ratios, similar to those found in liver. In brain tissue the ratio changed more slowly.
In vitro experiments
The in vitro incubations with radiolabelled GLA or LiGLA were performed for 72 h as the concentrations of GLA and DGLA in tumours grown in nude mice were relatively slow-changing with a concomitant increase of AA within 48-72 h after the infusion of LiGLA. Also, at this time point cells were 90% viable as determined by a routine Trypan Blue exclusion test. These results are consistent with those reported previously in which evidence of extensive cell death was not detected until day 6 (Begin et al, 1986; Begin and Ells, 1987) .
British Journal of Cancer (1997) 75(12) There were no significant differences in the metabolism of GLA when it was provided either in the form of free acid or lithium salt to cells grown in vitro. Thus, the graphs presented in this study were generated from either GLA or LiGLA experiments. Figure 5 shows the capability of AsPC-l, PC-3 and ZR-75-1 cells to produce DGLA, AA and the elongation products of both -22:3n6 and 22:4fn6 respectively -when GLA was provided in the medium. Significant differences were observed in the distribution of radioactivity among n-6 fatty acids in different carcinomas. At 72 h of incubation, ZR-75-1 cells produced the highest levels of AA with similar concentrations of GLA and DGLA. In contrast, AsPC-1 cells showed the highest levels of DGLA and the lowest concentrations of AA, whereas in PC-3 intermediate values were detected. These differences were reflected in the GLA+DGLA/AA ratios shown in each panel of Figure 5 .
DISCUSSION
The nude mouse model allowed us to examine in three distinct human carcinomas (with different growth rates, Figure 2 , and grown in male or female mice), the uptake (Figure 3 ) and bioconversion of GLA (Figure 4) intravenously administered in the form of the lithium salt. In this model, when malignant cells were coinjected in the presence of a membrane basement matrix (Matrigel), tumours grew well, maintaining their histopathological characteristics (data not shown). By using this technique tumour sizes and shapes were homogeneous and predictable and, in particular, the mammary carcinoma (ZR-75-1) cells did not require the normally used pretreatment with P-oestradiol (Osborne, 1985) .
Thus, effects due to supraphysiological hormonal concentrations in female mice and effects of exogenous hormones on the activity of A5-desaturase were avoided (Brenner, 1990) .
The different origins and biological characteristics of the carcinomas grown either in vivo or in vitro could be correlated with some differences in their metabolism of GLA. However, in the in vivo time course study similar levels of total radiolabelled fatty acids were found (Figure 3) . Relatively high concentrations of GLA and DGLA were found in all these tumours 72 h after LiGLA administration. There were no substantial differences in the GLA metabolism in host liver, plasma and brain of mice bearing either pancreatic, prostatic or mammary carcinomas (Figures 3 and 4) . These findings support and expand similar results from in vivo studies with a human ovarian carcinoma and host nude mouse tissues reported previously (de Antueno et al, 1996) .
The Li[1-'4C]GLA dose (2.5 mg kg-' for 30 min) was similar to that used in pancreatic cancer patients (Fearon et al, 1996) . Under these experimental conditions concentrations of about 0.4 jg ml' of n-6 fatty acids derived from radiolabelled GLA were reached in tumour tissue at 48-72 h after infusion. If these values are extrapolated to a dose that would be administered during a 24 h infusion (120 mg kg-') they might eventually be within the range of cytotoxic concentrations (5-50 ,ug ml-') for malignant cells according to in vitro studies (Begin et al, 1985) . Total radioactivity per gram of tissue did not vary for at least 96 h in tumour, brain, fat and testes/ovaries whereas in other host tissues labelling declined substantially (Figure 2 ). Thus repeat dosing may lead to a cumulative increase in concentration. A similar trend to accumulate these n-6 fatty acids may occur in humans as the results from experiments in which deuterated DGLA was administered to volunteers indicated that DGLA could be stored in brain and liver and remained in plasma (El Bustani et al, 1986) . In the present study, the concentrations of DGLA produced from radiolabelled GLA in brain tissue were practically constant for 4 days. This indicated that either GLA was incorporated from the plasma and further elongated or that DGLA was taken up directly from the plasma. The permeability of the blood-brain barrier for the highly lipophilic GLA and DGLA could be helpful in chemotherapy with n-6 fatty acids for tumours localized in the brain.
The higher initial amount (16-to 28-fold) of radiolabelled n-6 fatty acids taken up by the liver compared with that recovered in tumours may reflect differences in the vascularization of the liver and subcutaneously grown carcinomas and also differences in liver metabolism of fatty acids. This accumulation may be helpful in the management of liver metastasis. Subcutaneously transplanted tumours proliferate more rapidly than their blood supply (Morton et al, 1982) . This may partially explain the slower decay of radioactivity in tumour tissue relative to the liver within the 96-h period of the present experiment, although this explanation cannot account for the similar slow decay in brain and testes/ovaries, which may be related to the high lipid contents of these organs.
Similar differences between malignant and normal tissue uptake after 1 h of intravenous infusion of n-6 fatty acids were reported in early studies using tissues of the same origin, rat hepatoma and host rat liver (DeTomas and Mercuri, 1977) . This suggests that once the n-6 fatty acids were taken up and further metabolized by the tumour they were retained for a longer period of time than in the liver. Our findings with slow infusions of LiGLA are consistent with previous studies (Hassam and Crawford, 1978) in which almost one-half of the radioactivity recovered from the liver and plasma lipid fractions, 22 h after oral administration of ['4C]DGLA, was still present as DGLA, probably because of its slower 3-oxidation than that shown by GLA.
Extrapolations from in vitro to in vivo experiments must be made with caution. The pathways for showing how GLA was metabolized by human carcinomas in the experimental conditions of this study are presented in Figure 1 . The in vitro experiments demonstrated that pancreatic (AsPC-1), prostatic (PC-3) and mammary carcinoma (ZR-75-1) cells are all capable of incorporating GLA and producing DGLA and AA by the elongation and A5 desaturation systems ( Figure 5 ). AA was elongated to adrenic acid (22:4f_6) in very small amounts ( Figure 5 ). The low A5-desaturase activity detected in AsPC-1 and PC-3 carcinomas is common in malignant cells (Morton et al, 1979) . This low enzymatic activity may be partially attributed to the fact that these cell lines are from humans in which the A5 desaturase activity is low compared with other species (El Bustani et al, 1986) . However, substantial A5-desaturase activity was detected in ZR-75-1 cells ( Figure 5 ) and in other human hepatoma cells (Marra and Alaniz, 1992) . The metabolic pathways for n-6 fatty acids were also demonstrated in a human lung mucoepidermoid carcinoma grown in immunodeficient mice (de Antueno et al, 1988) .
In this study GLA, apart from being metabolized to DGLA and AA, was also available for incorporation as GLA into tissue lipids. However, the presence of GLA metabolites in tumour tissue does not necessarily reflect the ability of these tumours grown in vivo to elongate and further A5 desaturate GLA. These metabolites could have been taken up selectively by the tumours from the host plasma. The DGLA and AA levels detected in tumours grown in mice were to some degree related to those detected in vitro for each tumour tissue. However, the total percentage of AA in the in vivo studies was higher than that in the in vitro studies (Figures 4  and 5 ). It has been proposed elsewhere (Voss and Sprecher, 1988) that AA produced in liver can be transported and used for membrane synthesis in cells and tissues that do not have an adequate capacity to make sufficient AA from n-6 fatty acid precursors. However, it is likely that the altered radiolabelled fatty acid composition mirrors changes in the metabolic pathways of the tumours (DeTomas and Mercuri, 1977; Morton et al, 1982) .
In summary, these in vivo and in vitro experiments demonstrated that the elongation and A5 desaturation systems remained active in these human tissues after malignant transformation. The in vivo study showed that LiGLA was well tolerated by host mice and led to increases in GLA and DGLA in many tissues. The prolonged half-life (retention time) of these n-6 fatty acids in PC-3, AsPC-1 and ZR-75-1 human carcinomas compared with other major organs of the mouse may be important in therapy. ABBREVIATIONS GLA, gamma-linolenic acid (A6,9,1 2-octadecatrienoic acid); DGLA, dihomo-gamma-linolenic acid (A8,11,14-eicosatrienoic acid); AA, arachidonic acid (A5,8,11,14-eicosatetraenoic acid); ADA, adrenic acid (A7,10,13,16-docosatetraenoic acid); LiGLA, lithium gamma-linolenate; sp. act., specific activity.
